{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T08:59:02Z","timestamp":1782291542350,"version":"3.54.5"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T00:00:00Z","timestamp":1634688000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["NV19-07-00329"],"award-info":[{"award-number":["NV19-07-00329"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PRIN 2017 - N. 20178S4EK9"],"award-info":[{"award-number":["PRIN 2017 - N. 20178S4EK9"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG2015-17593"],"award-info":[{"award-number":["IG2015-17593"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG2017-20564"],"award-info":[{"award-number":["IG2017-20564"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70107825"],"award-info":[{"award-number":["70107825"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.ejca.2021.10.004","type":"journal-article","created":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T16:10:24Z","timestamp":1636819824000},"page":"72-79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocol"],"prefix":"10.1016","volume":"160","author":[{"given":"J.","family":"Stutterheim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"de Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.M.","family":"van der Sluis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Alten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Ancliffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Attarbaschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Aversa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4848-7789","authenticated-orcid":false,"given":"J.M.","family":"Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Biondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Brethon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2156-5230","authenticated-orcid":false,"given":"P.","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2955-4528","authenticated-orcid":false,"given":"G.","family":"Cazzaniga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Escherich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ferster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1836-4075","authenticated-orcid":false,"given":"R.S.","family":"Kotecha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Lausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9781-5908","authenticated-orcid":false,"given":"Alex WK.","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7976-3654","authenticated-orcid":false,"given":"F.","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Stary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Szczepanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.H.J.","family":"van der Velden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Vora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Zuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schrappe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.G.","family":"Valsecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Pieters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2021.10.004_bib1","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0140-6736(07)61126-X","article-title":"A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial","volume":"370","author":"Pieters","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2021.10.004_bib2","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1200\/JCO.19.00261","article-title":"Outcome of infants younger than 1 year with acute lymphoblastic leukemia treated with the interfant-06 protocol: results from an international phase III randomized study","volume":"37","author":"Pieters","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.10.004_bib3","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/pbc.25322","article-title":"Intensified chemotherapy without SCT in infant all: results from COG P9407 (cohort 3)","volume":"62","author":"Dreyer","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ejca.2021.10.004_bib4","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1038\/sj.leu.2404903","article-title":"Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: a final report of two consecutive studies, MLL96 and MLL98, of the Japan\u00a0Infant Leukemia Study Group","volume":"21","author":"Tomizawa","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2021.10.004_bib5","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1182\/blood.2019004741","article-title":"A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial","volume":"136","author":"Tomizawa","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2021.10.004_bib6","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/sj.leu.2404578","article-title":"Immunobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and type of MLL gene rearrangement","volume":"21","author":"Jansen","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2021.10.004_bib7","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1200\/JCO.20.02333","article-title":"Clinical implications of minimal residual disease detection in infants with KMT2A-rearranged acute lymphoblastic leukemia treated on the interfant-06 protocol","volume":"39","author":"Stutterheim","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.10.004_bib8","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/leu.2013.280","article-title":"Cytogenetics and outcome of infants with acute lymphoblastic leukemia and absence of MLL rearrangements","volume":"28","author":"De Lorenzo","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2021.10.004_bib9","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S1470-2045(10)70066-8","article-title":"Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97\/99 randomised trial","volume":"11","author":"Moorman","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.10.004_bib10","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.3324\/haematol.2014.122119","article-title":"Clinical and molecular genetic characterization of wild-type MLL infant acute lymphoblastic leukemia identifies few recurrent abnormalities","volume":"101","author":"van der Linden","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2021.10.004_bib11","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1182\/blood.2020009032","article-title":"Recurrent genetic fusions Redefine Mll-germline acute lymphoblastic leukemia in infants","volume":"137","author":"Fazio","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2021.10.004_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-021-01333-y","article-title":"Favorable outcome of NUTM1 -rearranged infant and pediatric B cell precursor acute lymphoblastic leukemia in a collaborative international study","author":"Boer","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2021.10.004_bib13","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.leu.2404586","article-title":"Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data","volume":"21","author":"van der Velden","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2021.10.004_bib14","first-page":"115","article-title":"MRD detection in acute lymphoblastic leukemia patients using Ig\/TCR gene rearrangements as targets for real-time quantitative PCR","author":"van der Velden","year":"2009"},{"key":"10.1016\/j.ejca.2021.10.004_bib15","article-title":"Human MLL\/KMT2A gene exhibits a second breakpoint cluster region for recurrent MLL\u2013USP2 fusions","volume":"vol. 33","author":"Meyer","year":"2019"},{"key":"10.1016\/j.ejca.2021.10.004_bib16","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/leu.2009.17","article-title":"Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol","volume":"23","author":"Van der Velden","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2021.10.004_bib17","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/bjh.13887","article-title":"New cellular markers at diagnosis are associated with isolated central nervous system relapse in paediatric B-cell precursor acute lymphoblastic leukaemia","volume":"172","author":"van der Velden","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2021.10.004_bib18","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1182\/blood-2009-10-248146","article-title":"Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFMALL 2000 study","volume":"115","author":"Conter","year":"2010","journal-title":"Blood"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921011473?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921011473?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:33:51Z","timestamp":1760733231000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921011473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":18,"alternative-id":["S0959804921011473"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.10.004","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocol","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}